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Abstract
Several genetic variants associated with platelet count and mean platelet volume (MPV) were recently reported in people of
European ancestry. In this meta-analysis of 7 genome-wide association studies (GWAS) enrolling African Americans, our aim
was to identify novel genetic variants associated with platelet count and MPV. For all cohorts, GWAS analysis was performed
using additive models after adjusting for age, sex, and population stratification. For both platelet phenotypes, meta-
analyses were conducted using inverse-variance weighted fixed-effect models. Platelet aggregation assays in whole blood
were performed in the participants of the GeneSTAR cohort. Genetic variants in ten independent regions were associated
with platelet count (N= 16,388) with p,561028 of which 5 have not been associated with platelet count in previous GWAS.
The novel genetic variants associated with platelet count were in the following regions (the most significant SNP, closest
gene, and p-value): 6p22 (rs12526480, LRRC16A, p = 9.161029), 7q11 (rs13236689, CD36, p = 2.861029), 10q21 (rs7896518,
JMJD1C, p = 2.3610212), 11q13 (rs477895, BAD, p = 4.961028), and 20q13 (rs151361, SLMO2, p = 9.461029). Three of these
loci (10q21, 11q13, and 20q13) were replicated in European Americans (N = 14,909) and one (11q13) in Hispanic Americans
(N = 3,462). For MPV (N= 4,531), genetic variants in 3 regions were significant at p,561028, two of which were also
associated with platelet count. Previously reported regions that were also significant in this study were 6p21, 6q23, 7q22,
12q24, and 19p13 for platelet count and 7q22, 17q11, and 19p13 for MPV. The most significant SNP in 1 region was also
associated with ADP-induced maximal platelet aggregation in whole blood (12q24). Thus through a meta-analysis of GWAS
enrolling African Americans, we have identified 5 novel regions associated with platelet count of which 3 were replicated in
other ethnic groups. In addition, we also found one region associated with platelet aggregation that may play a potential
role in atherothrombosis.
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Introduction
While platelets play a fundamental role in hemostasis, they are
also important in the development of atherosclerosis and arterial
thrombosis [1]. An elevated platelet count has been associated
with adverse clinical outcomes after thrombolysis or coronary
intervention in patients presenting with acute myocardial
infarction and moderate reductions in platelet count by thrombo-
poietin inhibition were associated with reduced thrombogenesis in
a primate model [2–4]. The heritability of variation in platelet
count is substantial with estimates ranging from 54% to more than
80% [5–8]. In the GeneSTAR study, a cohort included in the
current meta-analysis, the heritability of platelet count is 67% [9].
Like platelet count, an elevated mean platelet volume (MPV) is
also associated with adverse cardiovascular events and its reported
heritability is as high as 73% [8,10–12]. The heritability of MPV
in the GeneSTAR cohort was 71% [9]. Recent genome-wide
association studies (GWAS) and meta-analyses have identified
genetic variants associated with these two platelet traits in
Caucasians and a Japanese population [13–15]. A recent meta-
analysis in the CARe Project, involving genotyping of about
50,000 single nucleotide polymorphisms (SNPs) in 2,100 candidate
genes, also reported two genetic variants associated with platelet
count in African Americans [16]. The genetic variants reported to
date explain only a small fraction of the heritability in platelet
count and MPV, providing an opportunity for new studies to
discover additional genetic variants of importance [15]. Moreover,
African Americans have higher platelet counts than Caucasians
and additional genetic variants may contribute to this difference
[17]. Because of the different allele frequencies and linkage
disequilibrium patterns in populations of European and African
ancestry, we anticipated that we might discover new genetic loci
associated with platelet count and MPV in an African American
population compared to Caucasians [18].
We performed a meta-analysis of 7 GWAS studies that included
African-American subjects in the Continental Origins and Genetic
Epidemiology Network (COGENT) in order to identify novel
genetic variants associated with platelet count and MPV.
Results
We performed a GWAS analysis of platelet count in an African
American discovery sample of 16,388 individuals from 7
population-based cohorts (Table 1). The MPV meta-analysis
included all subjects from three cohorts and a subset of subjects
from two other cohorts (n = 4,531). Following stringent genotyping
and imputation quality control procedures (as outlined in the
Methods section), over 2.2 million SNPs were available for analysis
in each cohort (Table 1). The results of association studies and the
genomic-control corrected QQ plot for the combined African-
African GWAS analysis for platelet count and MPV are shown in
Figure 1 and Figure 2 and study specific QQ plots and genomic
inflation factors are reported in Figures S3 and S4 and Table S1.
The Jackson Heart Study (JHS) cohort contains a few hundred
related individuals. This resulted in a high genomic inflation factor
for platelet count and a few other traits, as previously described in
Lettre et al [19]. Within the CARe Consortium, Lettre et al have
done several analyses involving simulated phenotypes as well as
empirical data (lipids, BMI) and have shown that for JHS, genomic
control-correction is an appropriate way to control for the small
sub-group of related individuals. A list of all genome-wide
significant SNPs with regional plots for platelet count and MPV
can be found in Tables S2 and S3 and Figure S1. Cohort-specific
QQ-plots and association results for index SNPs associated with
platelet count or MPV are summarized in Figure S2 and Table S4.
Of the 10 loci on 7 chromosomes that reached GWAS threshold
(p,561028) in the platelet count meta-analysis, five have not been
reported in previous platelet count GWAS studies in any
population and 8 loci have not been reported previously in
African Americans (Figure 1). The MPV meta-analysis identified
three loci, each one on different chromosomes; two of these loci
were also associated with platelet count at GWAS threshold in the
current study (Figure 2). One MPV-associated locus has been
reported in African Americans before, and two of these three loci
have been associated with MPV in Caucasians in prior studies
[15,16]. A sex-specific meta-analysis did not reveal any heteroge-
neity for the allelic effect between the two sexes and did not
uncover any additional loci. Thus, the sex-specific results are not
reported here.
Identification of novel loci associated with platelet count
and replication in European Americans and Hispanic
Americans
The first of the novel loci from platelet count meta-analysis is
located on chromosome 6p22. The best SNP (rs12526480;
p = 9.161029) in this region is located in the intron of the
leucine-rich repeat containing 16A gene (LRRC16A). The minor
allele (G) of rs12526480 was associated with decreased platelet
count. Ten additional SNPs in the region had p,1026 (Table 2
and Table S2). The LRRC16A gene encodes a protein called
‘capping protein ARP2/3 and myosin-I linker’ (CARMIL), which
GWAS of Platelet Count and MPV in African Americans
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plays an important role in cell-shape change and motility. Genetic
variants in LRRC16A have been previously reported to be
associated with serum uric acid levels [20], nephrolithiasis [21]
and markers of iron status [22] but there have been no reports of
any association with either platelet count or other platelet
phenotypes. In the three European American cohorts,
rs12526480 was statistically significant in one cohort (p = 0.01)
and near nominal significance in the combined meta-analysis
(p = 0.06) with an effect size and direction similar to that observed
in African Americans. In Hispanic Americans, rs12526480 was
not significantly associated with platelet count (Table 3). Given the
proximity of the LRRC16A gene to the hemochromatosis (HFE)
gene and the well-known reciprocal relationship between platelet
count and iron stores, we additionally assessed the association
between rs12526480 and red cell phenotypes in the COGENT
African Americans. There was no evidence of association between
LRRC16A genotype and hemoglobin, hematocrit, red cell count or
mean corpuscular volume in the 16,388 African Americans, nor
was there any evidence of association between rs12526480
genotype and serum ferritin in 672 African Americans from
CARDIA or 2,126 from JHS. Nor did adjustment for red cell
phenotype or iron status alter the relationship between platelet
count and rs12526480 genotype. Finally, we had uric acid levels
available in 943 African Americans from CARDIA; again there
was no association with LRRC16A genotype (Table S5).
The second locus is on chromosome 7q11 where two SNPs in
intronic regions of the CD36 gene (rs13236689; p = 2.861029 and
rs17154155; p = 1.161028) reached GWAS significance threshold,
while 8 additional SNPs had p,1026. rs13236689 and
rs17154155 are in close linkage disequilibrium (r2 = 0.90 in the
HapMap Yoruban population). After conditioning on rs13236689
in the association analysis, rs17154155 did not remain statistically
significant (p = 0.39). Of the three European American cohorts,
rs13236689 was statistically significant in the WHI cohort
(p = 0.05) but not in the meta-analysis of all three studies
(p = 0.07, Table 3). The CD36 gene encodes a thrombospondin
receptor (platelet glycoprotein IV) which is present on the surface
of platelets and several other cells [23]. rs17154155 has been
reported to be associated with platelet function as well as with
platelet expression of CD36 [24,25].
In the third locus on chromosome 10q21, 71 SNPs reached
GWAS threshold and 57 additional SNPs had p,1026. Two non-
synonymous common variants of unknown functional significance,
rs 10761725 (resulting in serine to threonine substitution) and
rs1935 (resulting in glutamate to aspartate substitution), in this
region also crossed the GWAS threshold. All 128 SNPs in this
region appear to be in strong linkage disequilibrium based on
Yoruban HapMap data. The most significant SNP in this region,
rs7896518 (p= 2.3610212), is located in an intron of the jumonji
domain containing 1C (JMJD1C) gene. SNPs in this region have
been reported to be associated with MPV (rs2393967) and with
native platelet aggregation in platelet-rich plasma (rs10761741 in
Caucasians and rs2893923 in African Americans) but not with
platelet count [15,26]. For rs7896518, data were available from 2
European American cohorts and meta-analysis found a significant
association reaching GWAS threshold (p = 2.6161029) with
similar direction of effect size (Table 3).
The fourth novel locus was located on chromosome 11q13. The
most significant SNP (rs477895; p= 4.961028) was in an intron of
the BCL2-associated agonist of cell death (BAD) gene, while 23
other SNPs had p,1026. For rs477895, all replication cohorts had
effect sizes in a direction similar to African Americans and one
European American and the Hispanic cohorts reached statistical
Author Summary
The majority of the variation in platelet count and mean
platelet volume between individuals is heritable. We
performed genome-wide association studies in more than
16,000 African American participants from seven popula-
tion-based cohorts to identify genetic variants that
correlate with variation in platelet count and mean platelet
volume. We observed statistically significant evidence (p-
value,561028) that 10 genomic regions were associated
with platelet count and 3 were associated with mean
platelet volume. Of the regions that were significantly
associated, we found 5 novel regions that were not
reported previously in other populations. Three of these 5
regions were also associated with platelet count in
European Americans and Hispanic Americans. All these
regions contain genes that are either known to have or
potentially may have a role in determining platelet count
and/or mean platelet volume. We further found that one
of these regions was also associated with agonist-induced
platelet aggregation. Further studies will determine the
exact role played by these genomic regions in platelet
biology. The knowledge generated by this and other
studies will not only help us better understand platelet
biology but can also lead us to the discovery of new anti-
platelet drugs.
Table 1. Characteristics of COGENT African-American meta-analysis cohorts.**
ARIC CARDIA GeneSTAR HANDLS Health ABC JHS WHI
Sample size 2664 943 934 862 898 1992 8095
Study design* unrelated unrelated family unrelated unrelated unrelated unrelated
Age, years 53.4 (5.8) 24.4 (3.8) 45.2 (12.6) 48.2 (9.0) 73.4 (2.8) 50.0 (12.1) 61.6 (7.0)
Female (%) 63.2 58.7 61.6 56.0 58.8 61.2 100
SNPs (N) 2,799,937 2,813,829 3,181,434 3,021,329 3,129,972 2,819,255 2,486,528
Platelet count (109/L) 256.4 (65.7) 279.7 (71.4) 265.3 (67.0) 268.7 (76.8) 237.6 (71.6) 256.6 (64.5) 250.3 (60.1)
MPV*** 9.3 (0.9) fL NA 7.9 (0.9) fL 9.2 (1.0) fL 10.9 (1.6) fL 9.2 (0.9) fL NA
*All studies are population-based, in addition, JHS has a small group of related individuals.
**Mean (SD), and units (untransformed) that were used in the regression models for each trait.
***For MPV, complete cohorts of GeneSTAR, HANDLS, and JHS were included, while only a subset of ARIC (n = 644) and Health ABC (n = 182) were included.
NA= not available; MPV=mean platelet volume.
doi:10.1371/journal.pgen.1002491.t001
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significance (p = 4.4861023 and p= 0.04 respectively). Meta-
analysis of the three European American cohorts also found
significant association of rs477895 with platelet count
(P = 1.7161023, Table 3). The protein encoded by the BAD gene
inhibits the activity of the BCL-xL and BCL-2 proteins and thus
has a pro-apoptotic effect [27]. Phospholipase C b3 protein
Figure 1. Manhattan plot of the genome-wide association results for meta-analysis. (a) platelet count; (b) mean platelet volume. SNPs are
plotted on the x-axis according to their position on each chromosome against the negative log10 of p-values on y-axis. Names of the genes that
contain the significant SNPs or are located close to the significant SNPs are indicated on the plot adjacent to the significant SNPs. Names of genes in
the novel regions are in red.
doi:10.1371/journal.pgen.1002491.g001
Figure 2. Quantile–quantile (QQ) plots. (a) platelet count meta-analysis with all SNPs included; (b) platelet count meta-analysis after removing 1
million base pairs around the top SNPs from the 10 loci; (c) mean platelet volume meta-analysis. Blue dots are SNPs plotted on the x-axis of expected
p-value under the null hypothesis against the observed p-value in the study (p-values are plotted here as negative logarithm 10). The red diagonal
line represents the line of unity, the region where expected and observed p-values are the same under the null hypothesis. Black lines above and
below the red diagonal line bound 95% confidence intervals. Under the null hypothesis, SNPs should follow the line of unity closely except those
SNPs for which the null hypothesis is rejected. SNPs in the QQ plot for the platelet count meta-analysis do not follow the line of unity closely and this
appears to be due to large number of significant SNPs in the associated loci. When the chromosomal regions containing these loci are removed, the
appearance of QQ plot improves considerably.
doi:10.1371/journal.pgen.1002491.g002
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encoded by another gene at this locus, PLCB3, is also known to be
present in platelets and its deficiency results in impaired platelet
function in mice [28]. This locus also contains SLC22A11 and
SLC22A12, two genes that encode solute carrier proteins and
previous GWAS have found association of genetic variants in
these genes with serum uric acid levels [20]. Of the two genes, the
transcript of SLC22A11 is present in significant amount in
platelets as is the transcript for BAD [29]. Interestingly, a
SNP about 20 kbp upstream of SLC22A11, rs4930420, almost
reached GWAS threshold (p = 9.1661028, r2 with rs477895
= 0.21) and four additional SNPs in complete LD with rs4930420
(r2 = 1) had p-values,1026. By examining the actual linkage
disequilibrium patterns in this region in COGENT, and by
performing conditional regression analysis in more than 8,400
African Americans from the WHI cohort simultaneously
adjusting for BAD rs477895 and SLC22A11 rs4930420, we
demonstrate that there are likely at least 2 independent platelet
count association signals in this region and that the BAD and
PLCB3 polymorphisms appear to represent the same association
signal (Table S6).
The fifth novel locus was on chromosome 20q13 where one
SNP in the SLMO2 gene exceeded GWAS significance threshold
(rs151361; p = 9.461029) while 2 other SNPs had p,1026. One
of these two SNPs was located in the first intron of TUBB1 gene
(rs6070696; p = 2.561027) and was 16.3 kbp downstream of the
lead SNP (YRI HapMap r2 = 0.6). The TUBB1 gene encodes a
beta1 tubulin, which plays an important role in megakaryopoiesis
[30]. All replication cohorts had effect sizes in the direction similar
to African Americans for rs151361 but only one European
American study reached statistical significance (p = 0.01). The
meta-analysis of the three European American replication cohorts
also found a statistically significant association between rs151361
and platelet count (p = 1.161023, Table 3).
Validation of previously reported loci for platelet count
In addition to identifying novel loci, we also replicated 5
previously reported loci at GWAS significance threshold and 3
other loci that were highly significant in our study but not at
GWAS significance level (Table S7). The strongest signal in our
platelet count meta-analysis was from chromosome 6p21 (SNP
with the lowest p-value = rs210134; p = 2.3610215) located in the
BAK1 gene, a locus that has been reported previously in
Caucasians, Japanese, and African American populations [13–
16]. We also found strong associations between platelet count and
loci on chromosomes 6q23 (rs9494145; p = 2.861029), 7q22
(rs342293; p = 1.661028), and 12q24 (rs6490294; p = 4.861029),
all of which have been previously reported for Caucasians but not
for African Americans [15]. Finally, we confirmed the association
of a genetic variant rs8109288 (p= 5.0610210) in the tropomyosin
4 (TPM4) gene at chromosome 19p13 that has been previously
reported for African Americans in a candidate gene study [16]. In
our replication cohorts, rs8109288 was associated with platelet
count in meta-analysis of European American cohorts and in
Hispanic Americans (p = 2.661028 and 0.02 respectively). We
were also able to confirm the association of all previously reported
SNPs (or a nearby SNP in the same LD block) with platelet count
at a p,0.05 (Table S5).
Identification of loci for MPV
Of the three loci we identified at GWAS significance level for
MPV, 2 have been previously reported to be associated with MPV
in Caucasians, and one has been reported previously in African
Americans. The association which has been previously reported in
African Americans was of the A-allele of rs8109288 in TPM4 with
increased MPV (p= 3.361029); the same SNP was also associated
with platelet count in this study. TPM4, a protein with a major role
in stabilizing the cellular cytoskeleton, is present in platelets [31].
Table 2. Novel and validated loci based on genome-wide association with platelet count and mean platelet volume in COGENT
(novel loci are in bold).
Locus
Significant
SNPs (N)*
Top SNP in
region Position Candidate gene
Maj/Min
Allele MAF Effect size (SE) p-value Het-P (I2)
PLATELET COUNT
6p22 1 rs12526480 25641513 LRRC16A G/T 30.5% 24.39 (0.76) 9.1561029 0.62 (0)
6p21 20 rs210134 33648187 BAK1 A/G 28.6% 26.16 (0.78) 2.32610215 0.18 (10.6)
6q23 4 rs9494145 135474245 HBS1L, MYB C/T 7.3% 8.19 (1.38) 2.7961029 0.99 (0)
7q11 2 rs13236689 80073950 CD36 G/T 43.6% 4.18 (0.70) 2.8461029 0.73 (0)
7q22 4 rs342293 106159455 PIK3CG G/C 38.6% 24.05 (0.72) 1.5861028 0.18 (9)
10q21 71 rs7896518 64774506 JMJD1C G/A 32.4% 5.18 (0.74) 2.26610212 0.14 (16)
11q13 1 rs477895 63805488 BAD C/T 45.3% 24.19 (0.77) 4.9161028 0.17 (11)
12q24 26 rs6490294 110674821 ACAD10 C/A 33.7% 24.38 (0.75) 4.7861029 0.71 (0)
19p13 1 rs8109288# 16046559 TPM4 A/G 9.7% 28.72 (1.40) 5.02610210 0.35 (0)
20q13 1 rs151361 57047397 SLMO2, TUBB1 G/A 25.7% 4.49 (0.78) 9.4461029 0.04 (40)
MEAN PLATELET VOLUME
7q22 4 rs342296 106160139 PIK3CG A/G 37.2% 0.16 (0.02) 1.44610211 0.25 (0)
17q11 1 rs11653144 24699352 TAOK1 C/T 44.2% 20.13 (0.02) 4.1761028 0.48 (0)
19p13 1 rs8109288 16046559 TPM4 A/G 8.4% 0.26 (0.04) 3.3061029 0.84 (0)
*SNPs in locus reaching GWAS significant threshold (561028).
MAF=minor allele frequency; Chr = chromosome; SE = standard error; effect size = age-sex adjusted change in platelet count (109 L) or MPV (fL) per copy of minor allele;
Maj =major; Min =minor; Het-P = Cochrane Q p-value to assess heterogeneity.
#excluding cohorts that were included in the previous study16 that reported this SNP, the p-value was 8.661027.
doi:10.1371/journal.pgen.1002491.t002
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In the 7q22 region, we found that the SNP with the lowest p-value for
MPV (rs342296; p=1.4610211) was different from the SNP most
associated with platelet count (rs342293; p-value=5.84610211)
although the two SNPs were only 684 bp apart and are in the same
LD block (r2 =0.92 based on HapMap II YRI) [15]. We also
replicated a locus associated with MPV on 17q11 (rs11653144;
p=4.261028) at GWAS significance threshold [15]. Of the 10
additional previously reported loci for MPV, we found statistically
significant associations with 7 of them although these associations did
not reach GWAS significance threshold (Table S8). For the loci that
we were unable to replicate, we found other nearby SNPs with
p,0.05. The direction of effect for all SNPs was not similar to the
previously reported study of individuals of European ancestry
suggesting that the alleles at the causal loci may be different between
the two populations.
Platelet aggregation studies
Three regions (7q11, 7q22, 10q21) containing four SNPs
(rs13236689, rs342296, rs342293, rs7896518) have already been
shown to be associated with platelet aggregation [24–26,32].
Therefore, the SNPs with the lowest p-values in each of the
remaining 8 regions (Table 4) identified for either platelet count or
MPV were examined for their association with platelet aggrega-
tion in 832 African-American individuals from the GeneSTAR
study. Of the 8 SNPs, 3 were associated with a significant change
in agonist-induced platelet aggregation but only one exceeded the
Bonferroni-corrected significance threshold of 0.005 (Table 4).
The minor allele (C) of rs6490294 in the ACAD10 gene (12q24)
was associated with increased ADP-induced platelet aggregation
(p = 0.002). Variants in this region have been previously reported
to be associated with coronary artery disease [15]. The minor
allele (A) of the 2nd SNP, rs8109288, in the TPM4 gene, was
associated with decreased arachidonic-induced platelet aggrega-
tion (p= 0.03) and a trend towards decreased aggregation with
ADP (p= 0.09). The minor allele (G) of the 3rd SNP, rs151361, in
the SLMO2 gene, was associated with increased ADP-induced
platelet aggregation (p= 0.008). The last 2 SNPs were nominally
significant but did not exceed the Bonferroni-corrected signifi-
cance threshold.
Discussion
We report the first meta-analysis of GWA studies of platelet
count and MPV in a large number of African American
participants from 7 population-based cohorts. We have identified
5 novel loci associated with platelet count of which three were
replicated in the European American cohorts and one in the
Hispanic cohort. None of these new African-American platelet loci
have been reported previously in any racial group. In addition, we
have confirmed that several loci previously reported in Europeans
or Japanese are also associated with these platelet phenotypes in
African Americans. We have further shown that 3 of the 8 loci
(with one exceeding Bonferroni-corrected threshold), for which
there have been no previously known association with platelet
aggregation, are also associated with differences in platelet
function using a subset of our African American sample.
Interestingly, the 5 novel platelet count loci are intragenic and 4
of these genes are known to have some role in platelet formation or
biology. Platelets are small anucleate blood cells that are released
from the cytoplasm of much larger bone marrow precursor cells
known as megakaryocytes. One of the novel findings is the
association of LRRC16A gene with platelet count. The protein
encoded by the LRRC16A gene, capping protein ARP2/3 and
myosin-I linker (CARMIL), plays an important role in actin-based
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cellular processes. Actin filaments are essential for end-amplifica-
tion of pro-platelet processes during megakaryocyte maturation
[33]. CARMIL exposes the barbed ends of actin filaments by
binding to and then dislodging the capping protein from the actin
filament [34]. Capping proteins are up-regulated during mega-
karyocyte maturation and LRRC16A is differentially expressed in
megakaryocytes compared to other blood cells [35,36]. The
capping protein binding region of the CARMIL protein resides in
the later part of the protein (940–1121 amino acid residues), which
is a highly conserved region from protozoa to vertebrates. The
majority of the residues in this region are critical for the anti-
capping protein activity of CARMIL [37]. The rs12526480
genetic variant identified in our study is located in the latter part of
the gene and may be in LD with a functional mutation in this
conserved region. Any mutation that decreases the ability of
CARMIL to dislodge capping protein from the barbed ends of the
actin filament may result in abnormal megakaryocyte maturation
and decreased platelet formation which is consistent with the
direction of effect we observed in our study.
Another novel finding not reported in earlier GWA studies is
the association of platelet count with CD36, a gene that encodes a
receptor present on the surface of platelets, megakaryocytes, and
several other cells. CD36 has a wide variety of ligands including
thrombospondin [23]. Both CD36 and thrombospondin genes are
up-regulated during megakaryocyte maturation and binding of
thrombospondin-I to CD36 inhibits megakaryopoiesis, thus
potentially providing a feedback mechanism for control of
megakaryopoiesis [34,36,38]. The exact mechanism through
which activation of CD36 inhibits megakaryopoiesis is unclear
but may involve activation of extrinsic apoptotic mechanisms [39].
The most significant SNP associated with platelet count
(rs210134 in BAK1) in our study is in complete LD with the most
significant BAK1 SNP reported to be associated with platelet count
in individuals of European ancestry (rs210135, r2 = 1 with
rs210134 in HapMap II YRI, p= 2.18610214 in the current
study). While the magnitude of effect is similar, the direction of
effect is opposite suggesting that the allele at the causal locus is
different in the two ethnic groups. A candidate gene study in
African Americans has reported another SNP (rs449242, r2 = 0.81
with rs210134 in HapMap II YRI) in BAK1 and the direction of
effect is similar to our study (Table S5) [16]. In addition to
confirming the association of genetic variants in the pro-apoptotic
BAK1 gene with low platelet count, we have identified and
replicated a variant in another pro-apoptotic gene, BAD, that is
associated with low platelet count. The protein encoded by BAD
acts as a sensor for apoptotic signals upstream of BAK and
activates BAK through indirect mechanisms [27]. The identifica-
tion of these two genes in the intrinsic apoptotic pathway
highlights the importance of the apoptotic process in modulating
platelet lifespan in the circulation, which is one of the mechanisms
that regulate platelet count [40]. Interestingly, this region also
contains genetic variants associated with serum uric acid levels
[20], however, the mechanism through which uric acid levels may
be associated with platelet count remains unclear.
Genetic variants in the JMJD1C gene have been previously
reported to be associated with MPV in Caucasians but not with
platelet count. Conversely, we found several SNPs in this region
that reached GWAS significance threshold for association with
platelet count but none with MPV and we replicated the lead SNP
in European Americans at GWAS threshold. In a GWAS study of
platelet aggregation in Caucasians, the minor allele (T) of
rs10761741 was associated with an increase in epinephrine-
induced platelet aggregation in Caucasians [26]. JMJD1C gene is
a histone demethylase and appears to be involved in steriodogen-
esis [41]. In addition to its association with platelet aggregation
and MPV, previous GWAS have found genetic variants in this
gene to be associated with serum levels of alkaline phosphatase and
lipoprotein particle size and content [42–44].
In addition to confirming the finding of association of A-allele of
rs8109288 in TPM4 gene with lower platelet count [16] and
replicating this finding in European Americans, we also confirmed
the association of the A-allele of this SNP with increased MPV and
found a nominally significant association with decreased platelet
aggregation. TPM4 gene expression is higher in megakaryocytes
than other blood cells or other hematopoietic cells [35,45].
Tropomyosin proteins play a central role in actin-based cytoskel-
etal changes and there appears to be biological plausibility for an
effect of genetic variants on megakaryocyte maturation and
platelet aggregation [46].
The final novel locus in the SLMO2 gene was also replicated in
European Americans but SLMO2 gene has no known role in
megakaryocyte biology. However, the variant is located within
13 kb of the TUBB1 gene, which is essential in the formation of
normal mature platelets. The TUBB1 gene encodes beta1-tubulin
that is exclusively expressed in platelets and megakaryocytes and
forms a component of microtubules [30]. Loss of function
mutations in TUBB1 gene have been reported in the literature
and result in thrombocytopenia, large platelets, and increased risk
Table 4. Association of the top SNP from each locus with agonist-induced platelet aggregation in whole blood.
SNP Candidate gene (s) Allele (MAF) Arachidonic acid ADP Collagen
P-value ES P-value ES P-value ES
rs12526480 LRRC16A G (0.30) 0.38 0.320 0.13 0.453 0.51 0.252
rs210134 BAK1 A (0.29) 0.42 20.272 0.94 20.024 0.46 20.304
rs9494145 HBS1L, MYB C (0.07) 0.85 0.117 0.41 0.412 0.87 20.121
rs477895 BAD C (0.45) 0.33 20.333 0.25 20.338 0.93 0.034
rs6490294 ACAD10 C (0.34) 0.14 0.460 1.7761023 0.827 0.07 0.580
rs11653144 TAOK1 C (0.44) 0.57 20.181 0.15 20.414 0.12 20.659
rs8109288 TPM4 A (0.10) 0.03 21.171 0.09 20.698 0.35 20.533
rs151361 SLMO2, TUBB1 G (0.26) 0.54 0.213 7.9561023 0.698 0.11 0.578
Arachidonic acid 0.5 mmol/L, ADP 10 mmol/L, and collagen 5 mg/mL; MAF=minor allele frequency; ES = effect size.
Maximal aggregation was measured in ohms with impedance aggregometry 5 minutes after introducing agonist.
doi:10.1371/journal.pgen.1002491.t004
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of intracranial hemorrhage in men [47,48]. The G-allele of the
rs1513691 variant is associated with increased platelet count,
decreased MPV, and increased aggregation, which may point
towards a gain in function mutation in this region.
All previously reported loci that were also significantly
associated with platelet count or MPV at GWAS threshold in
our study have known biological roles in platelet biology. Two of
these regions, 6q23 and 12q24, have pleiotropic effects with the
6q23 region associated with several hematological traits [13,15,49]
and the 12q24 region associated with celiac disease and coronary
artery disease [15]. More importantly, we also found that the
12q24 locus was associated with platelet aggregation after
Bonferroni adjustment for multiple comparisons and thus may
provide a mechanistic explanation of its role in development of
coronary artery disease. The GG genotype of the most significant
SNP in the 7q22 region, rs342293, is known to be associated with
higher PIK3CG mRNA levels in platelets [32]. SNPs at this locus
are also associated with platelet aggregation, pulse pressure, and
carotid artery plaque [26,50,51]. TAOK1 is an important regulator
of the mitotic progression and may also play a role in the apoptosis
of cells [52,53].
Our study included over 16,000 participants with platelet count
and over 4500 participants with MPV measured and we were able
to identify loci that explain between 0.16–0.33% of the variance in
platelet count and loci that explain 1–1.5% of the variance of
MPV (Table S9). Overall, the loci we identified explain up to 7%
of the variance in platelet count and up to 6% of the variance in
MPV, assuming that the each of these loci is independent.
However, for both platelet count and MPV, the estimated
heritability is .50%. Therefore, for each of these traits, the
majority of heritability remains unexplained. One of the
limitations of GWA studies is the limited power to detect effects
caused by genetic variants with frequency ,5%. We hypothesize
that a significant proportion of the heritability of platelet count
and MPV may be explained by variants with frequency ,5%.
Alternatively, there may be a large number of additional common
variants that affect these traits, but have more modest effects.
In conclusion, we have conducted a meta-analysis of GWAS
studies of platelet count and MPV in a large African American
population and identified novel genetic variants in regions with
genes that are likely to have a role in platelet formation.
Furthermore, we have replicated 3 of the 5 novel loci in European
Americans and one in Hispanic Americans. The novel regions
identified may provide a focus for further research in improving
our understanding of the biology of megakaryocyte maturation
and platelet survival. In addition, we examined the effect of the
genetic variants associated with platelet count and MPV on
platelet function, and found 3 of these genetic variants to be
associated with agonist-induced platelet aggregation of which one
crossed Bonferroni-corrected significance threshold. Whether
these newly identified genetic variants contribute to the risk of
coronary artery disease or myocardial infarction, or to disorders
associated with hyper- or hypo-aggregation of platelets, merits
further investigation.
Methods
Subjects
The 7 studies included in this meta-analysis belonged to
COGENT and enrolled 16,388 African American participants.
The supplementary text contains a detailed description of each
participating COGENT study cohort (Text S1). All participants
self-reported their racial category. Additional clinical information
was collected by self-report and clinical examination. All
participants provided written informed consent as approved by
local Human Subjects Committees. Study participants who were
pregnant or had a diagnosis of cancer or AIDS at the time of blood
count were excluded. We also excluded subjects who were outliers
in the analysis of genetic ancestry (as determined by cluster
analysis performed using principal component analysis or multi-
dimensional scaling) or who had an overall SNP missing rate
.10%.
Platelet count and MPV measurements
Fasting blood samples for complete blood count (CBC) analysis
were obtained by venipuncture and collected into tubes containing
ethylenediaminetetraacetic acid. Platelet counts and MPV were
performed at local laboratories using automated hematology cell
counters and standardized quality assurance procedures. Methods
used to measure the blood traits analyzed in this study have been
described previously for ARIC, CARDIA, JHS, Health ABC,
WHI, and GeneSTAR [54–58]. Platelet count was reported as 109
cells per liter, and was recorded in all 16,388 study participants.
Information on MPV was available in a subset of 4,612
participants from five COGENT study cohorts (ARIC, GeneS-
TAR, Health ABC, HANDLS, and JHS) and was reported in
femto liters (10215 L). All the phenotypes were approximately
normally distributed and we did not perform any data transfor-
mations.
Genotype data and quality control
Genotyping was performed within each COGENT cohort using
methods described in Text S1. Affymetrix chips were used in the
ARIC, CARDIA, JHS, and WHI studies and Illumina chips were
used in GeneSTAR, HANDLS, and Health ABC. DNA samples
with a genome-wide genotyping success rate ,95%, duplicate
discordance or sex mismatch between genetic estimates of gender
and self-report, SNPs with genotyping failure rate .10%,
monomorphic SNPs, SNPs with minor allele frequency (MAF)
,1%, and SNPs that mapped to several genomic locations were
removed from the analyses. Because African-American popula-
tions are recently admixed, we did not filter on Hardy-Weinberg
equilibrium p-value. Instead, significantly associated SNPs were
later examined for strong deviations from Hardy–Weinberg
equilibrium and/or raw genotype data was examined for
abnormal clustering. Participants and SNPs passing basic quality
control were imputed to .2.2 million SNPs based on HapMap II
haplotype data using a 1:1 mixture of Europeans (CEU) and
Africans (YRI) as the reference panel. Details of the genotype
imputation procedure are described further under Supplemental
Methods. Prior to meta-analyses, SNPs were excluded if
imputation quality metrics (equivalent to the squared correlation
between proximal imputed and genotyped SNPs) were less than
0.50.
Platelet aggregation assays
Differences in platelet count may affect platelet function and
aggregation [59]. In addition, younger platelets have higher MPV
than older platelets and are more reactive [60]. We hypothesized
that the genetic variants that determine platelet count and MPV
may also affect platelet aggregation. To examine this hypothesis,
we used agonist-mediated platelet aggregation assays, which can
provide information about the different aspects of platelet
aggregation. For these assays, platelet aggregation agonists, such
as collagen or ADP, are added to whole blood or platelet-rich
plasma and platelet aggregation is measured after a specified
amount of time (300 seconds). We performed platelet aggregation
assays in the participants of the GeneSTAR cohort. Blood samples
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were obtained as described above, and platelet aggregation in
whole blood was measured as reported previously [57]. Briefly, in
vitro whole blood impedance in a Chrono-Log dual-channel
lumiaggregometer (Havertown, Pa) was performed after samples
were stimulated with arachidonic acid (0.5 mmol/L, intra-assay
CV=24%), collagen (5 mg/mL; intra-assay CV=9%), or ADP
(10 mmol/L; intra-assay CV=46%). Maximal aggregation within
5 minutes of agonist stimulation was recorded in ohms.
Data analysis
For all cohorts, genome-wide association (GWAS) analysis was
performed using linear regression adjusted for covariates,
implemented in either PLINK v1.07, R v2.10, or MACH2QTL
v1.08 [61,62]. Allelic dosage at each SNP was used as the
independent variable, adjusted for primary covariates of age, age-
squared, sex, and clinic site (if applicable). The first 10 principal
components were also incorporated as covariates in the regression
models to adjust for population stratification (Text S1). For
GeneSTAR, family structure was accounted for in the association
tests using linear mixed effect (LME) models implemented in R
[63]. Although the JHS has a small number of related individuals,
extensive analyses have shown that results were concordant using
linear regression or LME, after genomic control [19]. Therefore,
results are presented for JHS using linear regression. For imputed
genotypes, we used dosage information (i.e. a value between 0.0–
2.0 calculated using the probability of each of the three possible
genotypes) in the regression model implemented in PLINK or
MACH2QTL (for cohorts with unrelated individuals) or the
Maximum Likelihood Estimation (MLE) routines (for GeneS-
TAR).
For both platelet phenotypes, meta-analyses were conducted
using inverse-variance weighted fixed-effect models to combine
beta coefficients and standard errors from study level regression
results for each SNP to derive a combined p-value and effect
estimate [64]. Study level results were corrected for genomic
inflation factors (lGC) by incorporating study specific lGC
estimates into the scaling of the standard errors (SE) of the
regression coefficients by multiplying the SE by the square-root of
the genomic inflation factor. The inflation factors for all completed
analyses are presented in Table S1. To maintain an overall type 1
error rate of 5%, a threshold of a=561028 was used to declare
genome-wide statistical significance. Between-study heterogeneity
of results was assessed by using Cochrane’s Q statistic and the I2
inconsistency metric. Meta-analyses were implemented in the
software METAL [64] and were performed independently by two
analysts to confirm results. To examine whether there were any
differences between males and females, sex-specific GWAS were
conducted in each cohort. The results for each SNP were pooled
and heterogeneity of allelic effects between females and males was
examined using the meta-analysis methods as implemented in
GWAMA software [65].
To assess whether the loci previously reported to be associated
with the platelet phenotypes in Europeans, Japanese, and African
Americans were replicated in the COGENT African-Americans,
we examined the meta-analysis results for each index SNP in the
regions previously reported, including consistency of direction of
effect. If the reported index SNP was not significant at p,0.05 we
examined adjacent SNPs and reported the closest SNP with
p,0.05 along with its distance from the index SNP.
To examine the association of genotype on platelet aggregation
in the GeneSTAR cohort, linear mixed models were used with
additive models adjusting for age and sex, and taking into account
familial correlation between the individuals.
Supporting Information
Figure S1 Negative log(10) statistical significance plots of the
each local region with 500 kbp on either side of the top SNP
significantly associated with platelet count.
(PDF)
Figure S2 Negative log(10) statistical significance plots of the
each local region with 500 kbp on either side of the top SNP
significantly associated with mean platelet volume.
(PDF)
Figure S3 QQ plots of individual studies for platelet count
(PLT).
(PDF)
Figure S4 QQ plots of individual studies for mean platelet
volume (MPV).
(PDF)
Table S1 Genomic inflation factors for all GWAS analyses
included in the meta-analysis.
(PDF)
Table S2 List of all SNPs with p-values,1026 in the regions that
were significant at GWAS threshold in platelet count meta-
analysis.
(PDF)
Table S3 List of all SNPs that were significant at p-value,1026
in regions with at least one SNP with GWAS threshold in mean
platelet volume meta-analysis.
(PDF)
Table S4 Individual study results for the top significant SNP
from each region.
(PDF)
Table S5 Association analysis of rs12526480 SNP with selected
phenotypes.
(PDF)
Table S6 Conditional analysis of the significant SNPs in at the
11q13 locus for platelet count.
(PDF)
Table S7 Association of loci previously reported with platelet
count in Caucasians, Japanese, or African American populations
(from references 13, 15, and 16).
(PDF)
Table S8 Association of loci previously reported with mean
platelet volume in Caucasians (N= 13943)(from reference [15]).
(PDF)
Table S9 Percentage variance in phenotype explained by each
SNP for each study.
(PDF)
Text S1 Supporting Methods.
(DOCX)
Acknowledgments
The authors wish to acknowledge the support of the National Heart, Lung,
and Blood Institute and the contributions of the involved research
institutions, study investigators, field staff, and study participants of
Atherosclerosis Risk in Communities (ARIC), Coronary Artery Risk in
Young Adults (CARDIA), Jackson Heart Study (JHS), and Broad Institute
in creating the Candidate-gene Association Resource for biomedical
research (CARe; http://public.nhlbi.nih.gov/GeneticsGenomics/home/
care.aspx). The authors also wish to thank the investigators, staff, and
participants of GeneSTAR, Health ABC, Healthy Aging in Neighborhoods
GWAS of Platelet Count and MPV in African Americans
PLoS Genetics | www.plosgenetics.org 9 March 2012 | Volume 8 | Issue 3 | e1002491
of Diversity across the Life Span Study (HANDLS), and Women Health
Initiative (WHI) for their important contributions. A listing of WHI
investigators can be found at http://www.whiscience.org/publications/
WHI_investigators_shortlist.pdf. The authors also wish to acknowledge the
support of the GARNET Collaborative Research Group.
Author Contributions
Conceived and designed the experiments: RQ BMSMAN GLMAA DMB
SG ABZ ABS JGW LCB APR ERM. Performed the experiments: EZ YL
MAN WT LL MKE TBH MAA DMB ABZ ABS TBH JGW LCB APR
BAL ARF CK. Analyzed the data: RQ BMS LRY DMB TBH JGW APR
BAL CK. Contributed reagents/materials/analysis tools: BMS EZ MAN
YL WT LRY MKE SG MAA GL DMB ABZ ABS TBH JGW LCB APR
ERM BAL ARF CK. Wrote the paper: RQ DMB LCB APR. Interpreted
the results and revised the paper: RQ BMS EZ MAN YL WT LRY LL SG
MAA GL DMB JGW LCB ARF APR.
References
1. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med
357: 2482–2494.
2. Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, et al. (2007) Impact of
baseline platelet count in patients undergoing primary percutaneous coronary
intervention in acute myocardial infarction (from the CADILLAC trial).
Am J Cardiol 99: 1055–1061.
3. Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, et al. (2004)
Association of platelet count with residual thrombus in the myocardial infarct-
related coronary artery among patients treated with fibrinolytic therapy for ST-
segment elevation acute myocardial infarction. Am J Cardiol 94: 1406–1410.
4. Tucker EI, Marzec UM, Berny MA, Hurst S, Bunting S, et al. (2010) Safety and
antithrombotic efficacy of moderate platelet count reduction by thrombopoietin
inhibition in primates. Sci Transl Med 2: 37ra45.
5. Biino G, Balduini CL, Casula L, Cavallo P, Vaccargiu S, et al. (2011) Analysis of
12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions
to thrombocytopenia and thrombocytosis are inherited traits. Haematologica 96:
96–101.
6. Buckley MF, James JW, Brown DE, Whyte GS, Dean MG, et al. (2000) A novel
approach to the assessment of variations in the human platelet count. Thromb
Haemost 83: 480–484.
7. Evans DM, Frazer IH, Martin NG (1999) Genetic and environmental causes of
variation in basal levels of blood cells. Twin Res 2: 250–257.
8. Traglia M, Sala C, Masciullo C, Cverhova V, Lori F, et al. (2009) Heritability
and demographic analyses in the large isolated population of Val Borbera
suggest advantages in mapping complex traits genes. PLoS One 4: e7554.
9. Bray PF, Mathias RA, Faraday N, Yanek LR, Fallin MD, et al. (2007)
Heritability of platelet function in families with premature coronary artery
disease. J Thromb Haemost 5: 1617–1623.
10. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, et al. (2010) Mean
platelet volume as a predictor of cardiovascular risk: a systematic review and
meta-analysis. J Thromb Haemost 8: 148–156.
11. Goncalves SC, Labinaz M, Le May M, Glover C, Froeschl M, et al. (2011)
Usefulness of mean platelet volume as a biomarker for long-term outcomes after
percutaneous coronary intervention. Am J Cardiol 107: 204–209.
12. Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG (2011) High platelet
volume and increased risk of myocardial infarction: 39 531 participants from the
general population. J Thromb Haemost 9: 49–56.
13. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, et al. (2010) Genome-
wide association study of hematological and biochemical traits in a Japanese
population. Nat Genet 42: 210–215.
14. Meisinger C, Prokisch H, Gieger C, Soranzo N, Mehta D, et al. (2009) A
genome-wide association study identifies three loci associated with mean platelet
volume. Am J Hum Genet 84: 66–71.
15. Soranzo N, Spector TD, Mangino M, Kuhnel B, Rendon A, et al. (2009) A
genome-wide meta-analysis identifies 22 loci associated with eight hematological
parameters in the HaemGen consortium. Nat Genet 41: 1182–1190.
16. Lo KS, Wilson JG, Lange LA, Folsom AR, Galarneau G, et al. (2011) Genetic
association analysis highlights new loci that modulate hematological trait
variation in Caucasians and African Americans. Hum Genet 129: 307–317.
17. Segal JB, Moliterno AR (2006) Platelet counts differ by sex, ethnicity, and age in
the United States. Ann Epidemiol 16: 123–130.
18. Casto AM, Feldman MW (2011) Genome-wide association study SNPs in the
human genome diversity project populations: does selection affect unlinked
SNPs with shared trait associations? PLoS Genet 7: e1001266.
19. Lettre G, Palmer CD, Young T, Ejebe KG, Allayee H, et al. (2011) Genome-
wide association study of coronary heart disease and its risk factors in 8,090
African Americans: the NHLBI CARe Project. PLoS Genet 7: e1001300.
20. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, et al. (2009) Meta-analysis of
28,141 individuals identifies common variants within five new loci that influence
uric acid concentrations. PLoS Genet 5: e1000504.
21. Tore S, Casula S, Casu G, Concas MP, Pistidda P, et al. (2011) Application of a
new method for GWAS in a related case/control sample with known pedigree
structure: identification of new loci for nephrolithiasis. PLoS Genet 7: e1001281.
22. Benyamin B, McRae AF, Zhu G, Gordon S, Henders AK, et al. (2009) Variants
in TF and HFE explain approximately 40% of genetic variation in serum-
transferrin levels. Am J Hum Genet 84: 60–65.
23. Silverstein RL, Febbraio M (2009) CD36, a scavenger receptor involved in
immunity, metabolism, angiogenesis, and behavior. Sci Signal 2: re3.
24. Ghosh A, Murugesan G, Chen K, Zhang L, Wang Q, et al. (2011) Platelet
CD36 surface expression levels affect functional responses to oxidized LDL and
are associated with inheritance of specific genetic polymorphisms. Blood 117:
6355–6366.
25. Jones CI, Bray S, Garner SF, Stephens J, de Bono B, et al. (2009) A functional
genomics approach reveals novel quantitative trait loci associated with platelet
signaling pathways. Blood 114: 1405–1416.
26. Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, et al. (2010)
Genome-wide meta-analyses identifies seven loci associated with platelet
aggregation in response to agonists. Nat Genet 42: 608–613.
27. Danial NN (2008) BAD: undertaker by night, candyman by day. Oncogene 27
Suppl 1: S53–70.
28. Lian L, Wang Y, Draznin J, Eslin D, Bennett JS, et al. (2005) The relative role of
PLCbeta and PI3Kgamma in platelet activation. Blood 106: 110–117.
29. Bugert P, Kluter H (2006) Profiling of gene transcripts in human platelets: an
update of the platelet transcriptome. Platelets 17: 503–504.
30. Italiano JE, Bergmeier W, Tiwari S, Falet H, Hartwig JH, et al. (2003)
Mechanisms and implications of platelet discoid shape. Blood 101: 4789–4796.
31. O’Neill EE, Brock CJ, von Kriegsheim AF, Pearce AC, Dwek RA, et al. (2002)
Towards complete analysis of the platelet proteome. Proteomics 2: 288–305.
32. Soranzo N, Rendon A, Gieger C, Jones CI, Watkins NA, et al. (2009) A novel
variant on chromosome 7q22.3 associated with mean platelet volume, counts,
and function. Blood 113: 3831–3837.
33. Italiano JE, Hartwig JH (2007) Megakaryocyte Development and Platelet
Formation. In: Michelson AD, ed. Boston: Elsevier. pp 27–34.
34. Yang C, Pring M, Wear MA, Huang M, Cooper JA, et al. (2005) Mammalian
CARMIL inhibits actin filament capping by capping protein. Dev Cell 9:
209–221.
35. Watkins NA, Gusnanto A, de Bono B, De S, Miranda-Saavedra D, et al. (2009)
A HaemAtlas: characterizing gene expression in differentiated human blood
cells. Blood 113: e1–9.
36. Raslova H, Kauffmann A, Sekkai D, Ripoche H, Larbret F, et al. (2007)
Interrelation between polyploidization and megakaryocyte differentiation: a
gene profiling approach. Blood 109: 3225–3234.
37. Uruno T, Remmert K, Hammer JA, 3rd (2006) CARMIL is a potent capping
protein antagonist: identification of a conserved CARMIL domain that inhibits
the activity of capping protein and uncaps capped actin filaments. J Biol Chem
281: 10635–10650.
38. Lim CK, Hwang WY, Aw SE, Sun L (2008) Study of gene expression profile
during cord blood-associated megakaryopoiesis. Eur J Haematol 81: 196–208.
39. De Botton S, Sabri S, Daugas E, Zermati Y, Guidotti JE, et al. (2002) Platelet
formation is the consequence of caspase activation within megakaryocytes.
Blood 100: 1310–1317.
40. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, et al. (2007)
Programmed anuclear cell death delimits platelet life span. Cell 128: 1173–1186.
41. Kim SM, Kim JY, Choe NW, Cho IH, Kim JR, et al. (2010) Regulation of
mouse steroidogenesis by WHISTLE and JMJD1C through histone methylation
balance. Nucleic Acids Res 38: 6389–6403.
42. Chasman DI, Pare G, Mora S, Hopewell JC, Peloso G, et al. (2009) Forty-three
loci associated with plasma lipoprotein size, concentration, and cholesterol
content in genome-wide analysis. PLoS Genet 5: e1000730.
43. Wolf SS, Patchev VK, Obendorf M (2007) A novel variant of the putative
demethylase gene, s-JMJD1C, is a coactivator of the AR. Arch Biochem Biophys
460: 56–66.
44. Yuan X, Waterworth D, Perry JR, Lim N, Song K, et al. (2008) Population-
based genome-wide association studies reveal six loci influencing plasma levels of
liver enzymes. Am J Hum Genet 83: 520–528.
45. Komor M, Guller S, Baldus CD, de Vos S, Hoelzer D, et al. (2005)
Transcriptional profiling of human hematopoiesis during in vitro lineage-specific
differentiation. Stem Cells 23: 1154–1169.
46. Gunning P, O’Neill G, Hardeman E (2008) Tropomyosin-based regulation of
the actin cytoskeleton in time and space. Physiol Rev 88: 1–35.
47. Kunishima S, Kobayashi R, Itoh TJ, Hamaguchi M, Saito H (2009) Mutation of
the beta1-tubulin gene associated with congenital macrothrombocytopenia
affecting microtubule assembly. Blood 113: 458–461.
48. Navarro-Nunez L, Lozano ML, Rivera J, Corral J, Roldan V, et al. (2007) The
association of the beta1-tubulin Q43P polymorphism with intracerebral
hemorrhage in men. Haematologica 92: 513–518.
GWAS of Platelet Count and MPV in African Americans
PLoS Genetics | www.plosgenetics.org 10 March 2012 | Volume 8 | Issue 3 | e1002491
49. Ferreira MA, Hottenga JJ, Warrington NM, Medland SE, Willemsen G, et al.
(2009) Sequence variants in three loci influence monocyte counts and
erythrocyte volume. American Journal of Human Genetics 85: 745–749.
50. Bis JC, Kavousi M, Franceschini N, Isaacs A, Abecasis GR, et al. (2011) Meta-
analysis of genome-wide association studies from the CHARGE consortium
identifies common variants associated with carotid intima media thickness and
plaque. Nat Genet 43: 940–947.
51. Wain LV, Verwoert GC, O’Reilly PF, Shi G, Johnson T, et al. (2011) Genome-
wide association study identifies six new loci influencing pulse pressure and mean
arterial pressure. Nat Genet 43: 1005–1011.
52. Draviam VM, Stegmeier F, Nalepa G, Sowa ME, Chen J, et al. (2007) A
functional genomic screen identifies a role for TAO1 kinase in spindle-
checkpoint signalling. Nat Cell Biol 9: 556–564.
53. Wu MF, Wang SG (2008) Human TAO kinase 1 induces apoptosis in SH-SY5Y
cells. Cell Biol Int 32: 151–156.
54. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, et al. (1999)
Prospective study of markers of hemostatic function with risk of ischemic stroke.
The Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Circulation 100: 736–742.
55. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, et al. (2005)
Leukocyte count as a predictor of cardiovascular events and mortality in
postmenopausal women: the Women’s Health Initiative Observational Study.
Arch Intern Med 165: 500–508.
56. Nalls MA, Wilson JG, Patterson NJ, Tandon A, Zmuda JM, et al. (2008)
Admixture mapping of white cell count: genetic locus responsible for lower white
blood cell count in the Health ABC and Jackson Heart studies. Am J Hum
Genet 82: 81–87.
57. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, et al. (2008) Platelet
inhibition by aspirin 81 and 325 mg/day in men versus women without
clinically apparent cardiovascular disease. Am J Cardiol 101: 1359–1363.
58. Shimakawa T, Bild DE (1993) Relationship between hemoglobin and
cardiovascular risk factors in young adults. J Clin Epidemiol 46: 1257–1266.
59. Jennings LK, White MM (2007) Platelet Aggregation. In: Michelson AD, ed.
Platelets. 2nd ed. Boston: Elsevier. pp 495–507.
60. Harker LA, Slichter SJ (1972) The bleeding time as a screening test for
evaluation of platelet function. N Engl J Med 287: 155–159.
61. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence
and genotype data to estimate haplotypes and unobserved genotypes. Genet
Epidemiol 34: 816–834.
62. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
63. Chen MH, Yang Q (2010) GWAF: an R package for genome-wide association
analyses with family data. Bioinformatics 26: 580–581.
64. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics 26: 2190–2191.
65. Magi R, Lindgren CM, Morris AP (2010) Meta-analysis of sex-specific genome-
wide association studies. Genet Epidemiol 34: 846–853.
GWAS of Platelet Count and MPV in African Americans
PLoS Genetics | www.plosgenetics.org 11 March 2012 | Volume 8 | Issue 3 | e1002491
